Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arvinas Inc ARVN

Healthcare
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein... see more

Recent & Breaking News (NDAQ:ARVN)

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

GlobeNewswire 6 days ago

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

GlobeNewswire 9 days ago

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

GlobeNewswire 13 days ago

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire June 3, 2024

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

GlobeNewswire May 23, 2024

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

GlobeNewswire May 16, 2024

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

GlobeNewswire May 9, 2024

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 7, 2024

Arvinas to Present at Upcoming Investor Conferences

GlobeNewswire May 2, 2024

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

GlobeNewswire April 24, 2024

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

GlobeNewswire April 11, 2024

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire March 18, 2024

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire March 4, 2024

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire February 27, 2024

Arvinas Announces Chief Financial Officer Transition

GlobeNewswire February 20, 2024

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

GlobeNewswire February 20, 2024

Arvinas and Pfizer's Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

GlobeNewswire February 6, 2024

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

GlobeNewswire February 1, 2024

Arvinas Appoints Jared Freedberg as General Counsel

GlobeNewswire January 16, 2024

Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program

GlobeNewswire December 5, 2023